Incretin-Based Drugs Market Growth Forecast: Market Size, Key Trends And Emerging Opportunities Through 2030
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Incretin-Based Drugs Market Value Growth And Long-Term Outlook
The incretin-based drugs market has witnessed substantial expansion in recent years. This market is anticipated to expand from $27.83 billion in 2025 to $29.88 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.4%. The increase observed in the preceding period is attributable to factors such as the widespread prevalence of type 2 diabetes, existing insulin resistance rates, the rise in lifestyle-related metabolic disorders, the greater adoption of endocrinology drugs, and the establishment of hospital diabetes programs.
The incretin-based drugs market is anticipated to experience substantial expansion over the coming years. This market is projected to reach $39.25 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This projected growth stems from factors such as the global obesity epidemic, the increasing demand for weight management drugs, advancements in long-acting incretin innovation, the rise of personalized diabetes care, and a heightened focus on preventive metabolic health. Key developments expected during this period involve the swift embrace of GLP-1 receptor agonists, the broadening of indications for obesity management, a rise in the application of oral incretin therapies, the development of more combination therapy approaches, and enhanced patient adherence due to weekly dosing regimens.
Get A Free Sample Report With In-Depth Market Insights:
Incretin-Based Drugs Market Expansion Drivers: What’s Shaping Future Growth?
An increasing incidence of type 2 diabetes mellitus is anticipated to significantly boost the expansion of the incretin-based drugs market in the future. This condition is a persistent metabolic ailment marked by the body’s resistance to insulin and reduced insulin production, resulting in elevated blood sugar concentrations. Its widespread occurrence stems from unhealthy dietary habits and a lack of physical activity, which induce insulin resistance, diminishing the body’s capacity to manage blood sugar. Incretin-based medications manage type 2 diabetes by enhancing insulin secretion post-meals and decreasing glucagon output, thereby contributing to lower blood glucose. Furthermore, they extend gastric emptying time and suppress appetite, which assists in glycemic management and contributes to weight reduction. As an illustration, the National Health Service, a UK-based government department, reported in June 2024 that during 2023, approximately 549,000 additional individuals in England were identified as being at risk of developing type 2 diabetes, elevating the total pre-diabetic population to more than 3.6 million, representing a nearly 20% surge from 2022. Consequently, the increasing prevalence of type 2 diabetes mellitus is propelling the growth of the incretin-based drugs market.
Incretin-Based Drugs Market Segment Analysis Spotlighting Growth Areas
The incretin-based drugs market covered in this report is segmented –
1) By Type: Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Type 2 Diabetes, Obesity, Other Applications
Subsegments:
1) By Glucagon-Like Peptide-1 Receptor (GLP-1) Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide
2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin
Incretin-Based Drugs Market Strategic Trends: What Defines The Next Growth Phase?
Companies operating in the incretin-based drugs market are prioritizing the development of generic drug versions to offer more effective and patient-friendly treatment options for type 2 diabetes. A generic drug is a medication that possesses the same active ingredients, strength, dosage form, and route of administration as a brand-name drug, but it is marketed under its chemical name without brand labeling. For instance, in December 2024, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, introduced the first generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States. This product received Food and Drug Administration (FDA) approval. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, providing a new, more affordable option during ongoing shortages of GLP-1 medications.
Incretin-Based Drugs Market Leading Companies: Who Holds The Strongest Market Presence?
Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation
View The Full Incretin-Based Drugs Market Report:
Incretin-Based Drugs Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the incretin-based drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
